Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to ...

Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when treated with a ...

Among patients with prostate cancer, a high omega-3, low-omega-6 diet with fish oil led to a Ki-67 index decrease.

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

PORTOS can determine which patients with localized prostate cancer will benefit from dose-escalation of radiotherapy, data suggest.

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...